SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today shared details of ...
Generation Bio (GBIO) presented data on its cell-targeted lipid nanoparticle – ctLNP – and immune-quiet DNA – iqDNA – platforms at the European Society of Gene and Cell Therapy 31st Annual Congress.
WALTHAM, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...
Synthetic fertilizer has, until now, been the primary way for farmers to feed the world but is one of agriculture’s leading contributors to global greenhouse gas emissions and is a significant driver ...
GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cabaletta Bio ( (CABA)) has issued an ...
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback